Around 12+ key companies are developing the Marburg Virus Disease Therapies | DelveInsight

Around 12+ key companies are developing the Marburg Virus Disease Therapies | DelveInsight

DelveInsight’s “Marburg Virus Disease Pipeline Insight report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Marburg Virus Disease pipeline landscapes. It comprises Marburg Virus Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Marburg Virus Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Marburg Virus Disease pipeline products.    

 

Key takeaways from the Marburg Virus Disease Pipeline Report

  • DelveInsight’s Marburg Virus Disease Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Marburg Virus Disease treatment.
  • The leading Marburg Virus Disease Companies included such as Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario.
  • The promising Marburg Virus Disease therapies in the pipeline included such as Galidesivir, AVI-6003, AVI-7288, cAd3-Marburg, cAd3-EBO-S, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Marburg Virus Disease R&D. The therapies under development are focused on novel approaches to treat/improve Marburg Virus Disease.

 

Get an overview of the pipeline landscape @ Marburg Virus Disease Pipeline Outlook

 

Marburg Virus Disease Overview

Marburg Virus Disease is a highly virulent disease that causes haemorrhagic fever, with a fatality ratio of up to 88%. It is in the same family as the virus that causes Ebola virus disease. Human infection with Marburg Virus Disease initially results from prolonged exposure to mines or caves inhabited by Rousettus bat colonies. Once an individual is infected with the virus, Marburg can spread through human-to-human transmission via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids.

 

Latest Breakthroughs and Developments in the Marburg Virus Disease Treatment Landscape

  • BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to develop galidesivir to treat Marburg virus disease and potentially for other filoviruses, including the Ebola virus.
  • Integrated BioTherapeutics Inc. (IBT), in May 2021, announced the receipt of a contract valued at up to USD 16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal antibody for the treatment of Marburg virus disease (MVD).
  • BioFactura is developing a Marburg therapeutic in close collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). 
  • Batavia Biosciences has partnered with IAVI under an award they have received from the US Defense Threat Reduction Agency (DTRA) to develop a VSV-based vaccine against the Marburg virus. The VSV-Marburg vaccine candidate rVSVΔG-MARV-GP has been licensed by IAVI from the Public Health Agency of Canada and demonstrated strong protection from the deadly disease in non-human primate studies. 
  • Mapp Biopharmaceutical, Inc. has been given an advanced research and development contract for USD 16.5 million with options for an additional USD 30.0 million by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) to advance MBP091 through the completion of Phase 1 clinical trial. MBP091 is a single human monoclonal antibody (mAb) developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers that are caused by Marburg and the closely related Ravn virus.

 

Marburg Virus Disease Emerging Drugs

  • Galidesivir: BioCryst Pharmaceuticals
  • MVA-BN filovirus vaccine: Bavarian Nordic

 

Marburg Virus Disease Pipeline Therapeutics Analysis

There are approx. 12+ key companies which are developing the therapies for Marburg Virus Disease. The companies which have their Marburg Virus Disease drug candidates in the most advanced stage, i.e. phase II include, Bavarian Nordic.

 

DelveInsight’s Marburg Virus Disease Pipeline Report covers around 12+ products under different phases of clinical development like-

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

For further information, refer to the detailed report @ Marburg Virus Disease Emerging Therapies

 

Scope of the Marburg Virus Disease Pipeline Report

  • Coverage- Global
  • Marburg Virus Disease Companies- Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others
  • Marburg Virus Disease Therapies- Galidesivir, AVI-6003, AVI-7288, cAd3-Marburg, cAd3-EBO-S, and others
  • Marburg Virus Disease Therapeutic Assessment by Product Type
  • Marburg Virus Disease Therapeutic Assessment by Stage and Product Type
  • Marburg Virus Disease Therapeutic Assessment by Route of Administration
  • Marburg Virus Disease Therapeutic Assessment by Stage and Route of Administration
  • Marburg Virus Disease Therapeutic Assessment by Molecule Type
  • Marburg Virus Disease Therapeutic Assessment by Stage and Molecule Type
  • Marburg Virus Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Marburg Virus Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Marburg Virus Disease – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Mid Stage Products (Phase II)
  9. MVA-BN filovirus vaccine: Bavarian Nordic
  10. Early Stage Products (Phase I)
  11. Galidesivir: BioCryst Pharmaceuticals
  12. Inactive Products
  13. Marburg Virus Disease Key Companies
  14. Marburg Virus Disease Key Products
  15. Marburg Virus Disease- Unmet Needs
  16. Marburg Virus Disease- Market Drivers and Barriers
  17. Marburg Virus Disease- Future Perspectives and Conclusion
  18. Marburg Virus Disease Analyst Views
  19. Marburg Virus Disease Key Companies
  20. Appendix

 

Got Queries? Reach out for more information on the Marburg Virus Disease Pipeline Report- Marburg Virus Disease Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: